Bristol Myers Squibb (CELG-RI) Net Income towards Common Stockholders Growth (3y) (2012 - 2026)
Bristol Myers Squibb (CELG-RI) Net Income towards Common Stockholders Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
8.94% |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
76.51% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
131.31% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
109.43% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-51.68% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
-13.81% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
27.11% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-146.62% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
5.72% |
| 10 |
Bristol Myers Squibb |
- |
- |
8.07 Bn |
5.72% |
| Date | Value |
|---|
| Mar 31, 2026 |
5.72% |
| Dec 31, 2025 |
-18.75% |
| Sep 30, 2025 |
10.93% |
| Jun 30, 2025 |
-2.78% |
| Mar 31, 2025 |
24.27% |
| Dec 31, 2024 |
-68.24% |
| Sep 30, 2024 |
-7.90% |
| Jun 30, 2024 |
17.88% |
| Mar 31, 2024 |
-100.60% |
| Dec 31, 2023 |
29.45% |
| Sep 30, 2023 |
2.31% |
| Jun 30, 2023 |
153.17% |
| Mar 31, 2023 |
67.80% |
| Dec 31, 2022 |
55.30% |
| Sep 30, 2022 |
8.47% |
| Jun 30, 2022 |
2.24% |
| Mar 31, 2022 |
-7.40% |
| Dec 31, 2021 |
30.72% |
| Sep 30, 2021 |
-6.33% |
| Jun 30, 2021 |
52.42% |
